证券记录 · 已归档季度
KURA
Kura Oncology, Inc. · Healthcare · Biotechnology
10被追踪持有人
-1Δ持有人
11.52M持有股份
$100.37M报告持仓市值
+1新建仓位
−2清仓
动量输入（同类管理人）：
持有人广度 -9.1% ·
股份流向 +30.0% ·
净新建仓位 -10.0%
— 公式
集中积累 — 持股数量上升但持有人减少
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q4 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 85 | +3 | 46.85M | $513.57M | +7 | −4 |
| Q1 2026 | 85 | 0 | 43.54M | $354.05M | +5 | −5 |
| Q4 2025 | 85 | 0 | 47.00M | $488.20M | +1 | −1 |
| Q3 2025 | 15 | -1 | 31.70M | $280.57M | — | −1 |
| Q2 2025 | 13 | 0 | 25.43M | $146.75M | — | — |
| Q1 2025 | 10 | 0 | 9.58M | $63.25M | — | — |
| Q4 2024 | 10 | -1 | 11.52M | $100.37M | +1 | −2 |
| Q3 2024 | 10 | 0 | 4.92M | $96.24M | +1 | −1 |
| Q2 2024 | 10 | — | 4.04M | $83.12M | — | — |
持有人 · Q4 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (被动) | 3.35M | — | $29.14M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Millennium Management ✦ | 2.37M | +180.1% | $20.62M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 3 | Geode Capital Management ✦ (被动) | 1.78M | +0.1% | $15.53M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Geode Capital Management ✦ (被动) | 1.78M | +0.1% | $15.53M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | D. E. Shaw & Co. ✦ | 1.15M | +172.0% | $10.03M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 6 | D. E. Shaw & Co. ✦ | 1.15M | +172.0% | $10.03M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Citadel Advisors ✦ | 986.95K | -17.0% | $8.60M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | Marshall Wace ✦ | 948.90K | 新增 | $8.26M | 0.0% | New | 1 | SEC ↗ |
| 9 | Marshall Wace ✦ | 948.90K | 新增 | $8.26M | 0.0% | New | 1 | SEC ↗ |
| 10 | Marshall Wace ✦ | 948.90K | 新增 | $8.26M | 0.0% | New | 1 | SEC ↗ |
| 11 | Renaissance Technologies ✦ | 597.81K | +463.4% | $5.21M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 12 | Two Sigma Investments ✦ | 166.12K | -20.2% | $1.45M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 149.73K | +22.2% | $1.30M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 149.73K | +22.2% | $1.30M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 149.73K | +22.2% | $1.30M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 28.07K | +18.3% | $245,000 | 0.0% | ▲ Add | 3 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| Marshall Wace | $8.26M | 0.0% |
| Marshall Wace | $8.26M | 0.0% |
| Marshall Wace | $8.26M | 0.0% |
已清仓
| Point72 Asset Management | $3.70M | 曾为 0.0% |
| Wellington Management | $728,880 | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 217 持有人, 84.35M 股份, $677.88M 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
公开市场买入 (P)
Aug 24
WILSON TROY EDWARD
Officer, Director · President and CEO · 100.00K 股 @ 12.39 · $1.24M
Aug 17
WILSON TROY EDWARD
Officer, Director · President and CEO · 100.00K 股 @ 11.12 · $1.11M
公开市场卖出 (S)
Aug 21
Powl Brian T.
Officer · 4.34K 股 · $51,663
Aug 19
Bair Teresa Brophy
Officer · 31.49K 股 · $397,681
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
Aug 14
SC 13G/A — MONTANOVA CAPITAL, LLC
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q4 2024 ·
方法论 ·
通过API获取此数据